• Non ci sono risultati.

Economical aspects of Point of Care testing: not that simple.


Academic year: 2021

Condividi "Economical aspects of Point of Care testing: not that simple."


Testo completo


60 Riv Med Lab - JLM, Vol. 2, N. 1, 2001

The last two years Point of Care testing has made si- gnificant progress. Not only has the quality of the analyzers and tests increased considerably, also new possibilities have been made available concerning management of the point of care program. Recently we decided our laboratory had to take responsibility for all point of care testing done in our adult and paediatric, 1042 bed, university hospital. In order to be able to control a point of care program in our ho- spital, we developed a strategy to introduce point of care, create acceptance in the clinic, the laboratory and with the administration. In addition, we can control the quality of care and monitor the amount and nature of point of care tests performed.

Factors to consider when assessing costs of point of care are many. The calculation of the actual costs is difficult, because introduction of Point of Care Testing has an impact on many different aspects of the clinical laboratory. In addition, factors affecting the efficiency and the quality of care in the clinic should be considered.

We chose for an integrated approach, where as many test as possible are done on one or two types of analyzers connected to one central computer at the laboratory. Connection to the Hospital Information System (HIS) is a prerequisite. In this way all test results are recorded, can be traced and billed. The

connection between the central POC computer and the HIS is an expensive option, but necessary.

We calculated actual costs of tests done at the cen- tral laboratory considering: invested time needed at the ward to order the test in the usual manner with a requisition form; time and costs for the technician to come to the department to take the blood sample (or when send to the lab), time and costs in performing the analysis; time and costs in reporting the result.

All this was done also for the same test in a point of care setting. Apart from the material costs and the ti- me invested, we also tried to evaluate clinical bene- fits and possible savings as a consequence of these.

Less blood transfusions at the NICU, shorter stay at the ICU, shorter stay in the hospital, more direct and efficient management of “low-glucose neonates” are examples of such clinical benefits. The savings be- cause of these factors are difficult to calculate.

In our situation, the introduction of point of care te- sting helps us to discontinue the nightshift at the paediatric hospital (2.2 fte). At the other hand, a POC coordinator at the laboratory is necessary.

In general we find that point of care testing stimula- tes interaction between the clinic and the laboratory and improves patient care. These matters should be taken into account when addressing cost – benefit issues.

Economical aspects of Point of Care testing: not that simple.

Wouter W. van Solinge

Department of Clinical Chemistry, University Medical Center Utrecht, The Netherlands.

Corrispondenza a: w.w.vansolinge@azu.nl


Documenti correlati

Two views of digital terrain models for a number of southern hemisphere regions (and Maftet on the small lobe) that highlight the di↵erence in overall slope between the Anhur and

than the base-width which is around 100 nm. Electrons are not extracted in the collector as it remains floating. Therefore, the number of charge carriers in the base rises above

Nevertheless, following the declaration of lockdown, such technocratic politics based on a strong dialogue between government and experts with a progressive marginalisation

The patient presented in the clinical case, even though not showing hepatic metastases during diagnosis, developed secondariness two years after surgical operation.. Actual guide

Preliminary evidences about the sample composition, values of mean and Gini index of annual labour income, mean value of the WFH attitude index and share of employees with

Among the 371 patients treated with a first-line pertuzumab-/trastuzumab-based regimen, the overall mPFS was 16 months (95% CI, 13–19), with a significant improvement with respect